BioSpace News Archive

Takeda and Protagonist Therapeutics, Inc., announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in February.

Vanda Pharmaceuticals Inc. announced it will release results for the fourth quarter and full year 2023 on Wednesday, February 7, 2024, after the market closes.

DermTech, Inc. announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.

Brisk Health proudly announces its arrival in Denver, Colorado, revolutionizing healthcare accessibility for residents in the Mile-High City.

BioCareSD, a leading specialty distributor for orphan, rare and ultra-rare diseases, announced today that they have added RENFLEXISâ, a biosimilar to REMICADEâ, to their ever-expanding portfolio of therapies.

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories announced that data from the pivotal Phase 3 ALLELE study of tab-cel, approved in the European Union in adults and children two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease following solid organ transplant or hematopoietic cell transplant, were published for the first time online in The Lancet Oncology.

CONMED Corporation announced financial results for the fourth quarter and full-year ended December 31, 2023.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on January 31, 2024.

Rapafusyn Pharmaceuticals is pleased to announce two presentations at the Second Annual Molecular Glue Drug Discovery Summit